Share our Story
Learn about our Company
ABOUT 3BL Media, LLC
3BL Media provides a cloud-based, multi-channel news and content distribution platform for innovative companies.
Journalists, investors, customers and other stakeholders now have more choices than ever as to where and how they get their news and information. From email to news terminals to social media platforms and web portals, many options are available. And different people respond differently to various message formats: blogs vs. press releases vs. videos vs. articles.
3BL Media clients know that distributing multiple message formats, through multiple channels, produces results.
The Distribution Revolution(tm) means that organizations can distribute their press releases, blogs, videos and other media assets through social media, new media and traditional media channels, creating the greatest opportunity for the target audience to encounter and interact with your content.
CVS Addresses High Cost of Drugs; United Healthcare, CBS EcoMedia Support New Vegetable Garden in Green Bay; GlaxoSmithKline Cancer Drug Trial has Successful Results - Health Minute for October 11, 2012
A new survey by CVS Caremark of more than 2,400 of its retail pharmacists concludes that 62 percent of Americans believe the high cost of drugs is the biggest reason why as many as three out of four don’t take medications as prescribed. Non-adherence results in an estimated $300 billion a year in additional U.S. health care spending.
United Healthcare is supporting an innovative new Edible Landscape Garden in Green Bay, Wisconsin to provide healthy, affordable vegetables for the local community. Working through CBS EcoMedia’s WellnessAd program that connects advertisers with health and wellness projects in communities across the country, United Healthcare funding and volunteers have helped prepare the garden for planting next spring.
GlaxoSmithKline has announced that the Phase III study comparing the effectiveness and safety of its drug to treat renal cell carcinoma has resulted in a statistically significant outcome in its favor for 11 of the 14 domains from four Quality of Life categories. The drug, pazopanib, was first approved by the FDA in October 2009 and has received conditional marketing authorization in the E.U. in 2010.
For more information on these and other stories, go to 3blmedia.com